Jiangfan Wu
Contact
|
Department für Pharmazie Room Nr.: B2.002 |
 |
About
I Studied clinical pharmacy since 2016 in China and have experience in hospital practice.
Research Interest
I am interested in precision drug delivery guided by modeling. The current research direction is physiologically based pharmacokinetic modeling.
Publications
- Wu J, Zhao X, et al. Metabolic effects of the dual SGLT 1/2 inhibitor sotagliflozin on blood pressure and body weight reduction in people with diabetes: An updated analysis of randomized controlled trials[J]. Journal Of Diabetes and its Complications, Dec 2022. 36. 12.108352. (first author) http://doi.org/10.1016/j.jdiacomp.2022.108352
- Zhao X, Wu J, et al. A bibliometric analysis of WOSCC international pharmaceutical care practice between 2005-2020[J]. Chinese Journal of Hospital Pharmacy: Mar. 2023, Vol43: No.5.561-567.
- Wang X, Wu J, et al. Research Landscape of Physiologically Based Pharmacokinetic Model Utilization in Different Fields: A Bibliometric Analysis (1999-2023) [J]. Pharm Res (2024). https://doi.org/10.1007/s11095-024-03676-4.
- Zhao X, Wu J, et al. Ocular disorder associated with PCSK9 inhibitor: A pharmacovigilance disproportionality analysis[J]. British Journal of Clinical Pharmacology, 2023. 89. 2:458-469.
- Ma P*, Shang S*, Liu R, Dong Y, Wu J, et al. Prediction of teicoplanin plasma concentration in critically ill patients: a combination of machine learning and population pharmacokinetics[J]. Journal of Antimicrobial Chemotherapy, 2024, dkae292, https://doi.org/10.1093/jac/dkae292
- Wu J, et al. Concomitant use of sodium-glucose cotransporter 2 and metformin and the risk of osteomyelitis reporting: A disproportionality analysis for signal detection among patients with type 2 diabetes[J]. Expert Opinion on Drug Safety (under review/first author)